The aim of this study was to prepare an inclusion complex of Olmesartan Medoxomil, a novel angiotensin II Type 1 (AT1) receptor antagonist with B-cyclodextrin (B-CD) to improve its apparent solubility, dissolution rate and stability. Olmesartan Medoxomil, a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist, is a highly crystlline powder which is practically insoluble in water. Because of its limited aqueous solubility it exhibits poor dissolution characteristics and its oral absorption is dissolution rate limited. In this study the effect of β- cyclodextrin (βCD) on the aqueous solubility and dissolution rate of Olmesartan Medoxomil was investigated. Phase solubility profiles indicated that the solubility of Olmesartan Medoxomil was significantly increased in the presence of β-cyclodextrin and was classified as AL-type, indicating the formation of 1:1 stoichiometric inclusion complexes with a stability constant of 86.38. Solid complexes prepared by Neutralization method were investigated in solid state By UV Spectrophotometry and characterized by Fourier transform infrared spectroscopy, X-ray Diffraction & Scanning Electron Microscopy. Olmesartan Medoxomil Solubility significantly improved by complexation with β-cyclodextrin with respect to the drug alone.
Loading....